BOSHOFF CHRISTOFFEL, an Executive Vice President at Pfizer (PFE), has demonstrated a consistent pattern of selling company stock over the past several years, with no recent purchases recorded. According to SEC Form 4 filings, Christoffel has executed 27 transactions exclusively involving PFE shares, with total sales exceeding $1.99 million compared to total buys of $530,335.65. The sales have been structured across multiple transactions, often clustered around late January and February—a period frequently associated with executive stock vesting schedules. Notable dispositions include a $340,732.28 sale on January 30, 2026, followed by additional sales totaling $207,186.93 in late February 2026. Earlier filings reveal similar activity, including a $263,715.97 market sale on February 22, 2025, and a $319,247.76 transaction on January 31 of the same year.
The transactions, coded primarily as "F" (indicating sales to cover tax obligations or exercise costs) and occasionally "M" (open market sales), suggest a recurring liquidation strategy rather than discretionary market timing. While the sales are substantial—ranging from smaller dispositions like $8,328 on February 24, 2024, to larger ones exceeding $300,000—Christoffel has not engaged in any recent buying activity. The absence of open-market purchases since at least 2024 reinforces a net reduction in holdings, though the retained position size remains undisclosed in the filings. The pattern aligns with typical executive stock plan dispositions, emphasizing liquidity events over directional sentiment on the company’s stock.
AI-assisted summary